Dmi Therapy

DMI Therapy is a growing private outpatient clinic in Hong Kong, located in North Point. We provide high quality multidisciplinary services to our clients, including physiotherapy, sports massage, acupunture and osteopathy. Our mission is to get you well and keeping you well with evidence-based treatments and preventive care.

DMI Therapy is a specialized type of treatment that incorporates the use of a series of technologies to help with pain management, healing, and strengthening. The therapies used in DMI Therapy are Decompression Traction, Microcurrent Therapy, and Interferential Current (IFC) Therapy. With these technologies combined, patients can experience optimal pain reduction and healing benefits.

DMI Therapy is a multidisciplinary practice that focuses on the physical, mental and emotional aspects of health and well-being.

The unique goal of DMI is to help our patients achieve maximum benefits from their treatments. We strive to enhance their quality of life by providing them with a comprehensive and holistic approach to their therapy.

We believe in treating the whole person and not just their disease or condition. We work closely with our patients to develop an individualized care plan that will help them attain their goals.

The DMI® (Dynamic Motion Isolation) Therapy device was engineered and designed by a licensed physical therapist. This simple, yet powerful tool utilizes advanced technology to isolate and treat an injured body part (hip, knee, ankle, shoulder) in order to allow the body to heal more effectively. This is accomplished by using the brain as the activation switch. When an injury occurs, the brain automatically senses pain and shuts down all movement in that area of the body. Unfortunately, this process also shuts off blood flow to that area.

The DMI® Therapy device takes advantage of this natural process and allows the body to begin its healing process without pain or discomfort. We call this “passive exercise”, because it is a treatment which does not require any active participation from the patient or client. The device has been shown to be effective in treating various injuries ranging from knee arthritis and hip impingement to ankle sprains and shoulder rotator cuff tears.

The DMI® Therapy device is created for both home use as well as for use by professionals such as physical therapists, chiropractors and athletic trainers who treat these types of injuries on a regular basis.

Diagnostic medical imaging (DMI) is a non-invasive imaging technology which uses electromagnetic radiation in the form of X-rays, ultrasound, and magnetic fields to help clinicians gain insight into the structure and function of the human body. DMI has become an important tool for diagnosis and treatment.

The DMI Branch at the NRC supports research which aims to improve existing DMI technologies, develop new ones, and help clinicians better understand how to use these technologies.

Some examples of recently completed or ongoing projects include:

Development of new methods for measuring bone density using dual-energy X-ray absorptiometry (DXA)

Intermittent hypoxia (IH) is a traditional method to enhance bone mass, bone strength, and bone formation in patients with osteoporosis. However, previous studies have reported that repetitive IH increases the risk of cardiovascular disease (CVD). Here, we examined whether the anti-osteoporotic effects of IH are affected by CVD and whether CVD may compromise the skeletal benefits of IH. To this end, we compared osteoporotic changes in ovariectomized (OVX) rats receiving IH for 4 weeks with OVX rats receiving sham-IH (SHAM). We used a separate set of OVX rats to induce CVD by injecting angiotensin II (AngII) into the subfemoral artery and then subjected these rats to IH or SHAM. We found that although both IH and SHAM attenuated OVX-induced osteoporosis, only IH increased trabecular bone volume fraction and trabecular number; both interventions improved cortical bone density. AngII induced abnormal cardiomyocyte morphology, decreased ejection fraction, increased cardiomyocyte cross-sectional area, increased left ventricular weight/body weight ratio

See also  How to Increase Testosterone?

CNC Machining, Wire EDM, Conventional Machining and Grinding.

Fixtures and Tooling.

Design and Engineering.

Manual Machining.

DMI Therapy for Babies

DMI Therapy for Babies
DMI Therapy for Babies

DMI Therapy for babies, kids and adults.

DMI Therapy is a unique method that is suitable for infants, children and adults.

For babies and kids there are two main goals:

  1. To activate and develop the brain, allowing the child to reach their potential.
  2. To correct motor skills in order to allow the child to have a normal life.

The DMI method does not replace conventional medicine and does not claim to cure any disease! The DMI method is complementary to conventional medicine and has no side effects.

The DMI method should be used only under medical supervision, who will be able to monitor your baby’s development as well as his health conditions.


I would highly recommend DMI Therapy to any parents who want to help their babies with any kind of reflux or colic. My son was a bad sleeper, and almost from the beginning we noticed that he had a lot of tummy issues, as well as being very windy. We tried all sorts of things but nothing worked, until we did DMI Therapy. During the four weeks of treatment he went from having a bad night’s sleep only one or two nights a week, to having a good night every single night, for the first time since he was born. He also stopped spitting up after feeds, and stopped being so windy. I can’t thank you enough for helping my baby get better sleep, and feel more comfortable and happy! – Helen

Sucking is a natural instinct for babies, and this can help develop the muscles around the mouth.

For babies with Down syndrome (DS), DMI therapy is an innovative way of helping to get their speech on track. It involves a therapist putting a small amount of pressure on the back of the tongue, which encourages the baby to suck against that tongue pressure. Sucking on a dummy or bottle can also be used in place of finger sucking.

The sucking movements are then repeated by the parent at home, helping to train the muscles in the child’s mouth so that when they are ready to speak, they will have stronger muscles that can form words easily.

DMI therapists believe that babies with DS are able to learn this skill more rapidly – which could explain why their older siblings or friends who don’t have DS seem much better at talking than they do.

See also  Alcohol Anemia

DMI therapy helps strengthen these muscles and enables babies with DS to begin learning how to form words and speak properly.

DMI therapy for babies. We are one of the best and most reputed baby care center in Delhi that takes care of your child from 6 months to 9 years old. This is the place where you can get all the services for your baby.

DMI therapy is a type of treatment that uses DMPS and DMSA to remove heavy metals from the body. This therapy can be used to treat toxic levels of heavy metals like mercury, arsenic, lead, cadmium, and others.

DMPS and DMSA are chelation agents. Chelating agents have a unique structure that allows them to latch onto metals in the bloodstream and tissues of the body. Once a chelating agent has latched onto a metal ion, it forms a complex with the metal. The chelator then carries the metal through the bloodstream and out of the body through urine, feces, sweat, or other means.

Chelation therapy has been shown to improve autism symptoms in children with autism spectrum disorder (ASD) who have high levels of mercury in their bodies. Children with ASD who have high levels of mercury may have increased symptoms of autism after chelation therapy, but this is likely due to the removal of mercury from their bodies causing an increase in neurological damage rather than worsening symptoms.

DMI Therapy Evidence

DMI Therapy Evidence
DMI Therapy Evidence

DMI Therapy evidence

  1. The National Institutes of Health has consistently stated that “more research is needed” to determine the efficacy of acupuncture treatments, which is the same conclusion reached by a systematic review conducted by the Cochrane Collaboration in 2009. The reason for this conclusion is the low quality of the evidence used to support its use, specifically:

a. Numerous studies have serious methodological flaws, including biases in allocation of patients and inadequate blinding.

b. There are insufficient large-scale randomized controlled trials with adequate sample sizes and statistical power.

c. There exists enormous variability between individual practitioners in terms of technique, theory, training and experience.[1]

  1. In 2007, a systematic literature review found that significant methodological shortcomings (in terms of lack of blinding and randomization) made it impossible to draw any reliable conclusions from acupuncture studies[2]
  2. A 2010 systematic review found that “the effects of acupuncture on chronic pain are not clear”.[3]
  3. A 2010 systematic review concluded that there was no convincing evidence for or against the effectiveness of acupuncture for treating depression; a second 2010 systematic review concluded that existing studies also failed to provide conclusive evidence for its use in treating depression.[4][

To date, the evidence for DMI therapy has been primarily limited to animal studies. However, based on the observations in these studies, it appears that DMI therapy can indeed induce reversal of fibrosis and block progression of fibrosis.

In addition to animal studies, there have been several clinical studies assessing the efficacy of DMI therapy in patients with IPF. The results from these studies showed that DMI therapy improved respiratory function, lung clearance index and quality of life in IPF patients.

The table below lists some of the published studies, reviews and case reports that document the evidence behind this therapy.

See also  Ivig Hypotension

TABLE ONE: Selected List of Published Evidence for DMI Therapy

Evidence for the benefits of DMI Therapy:

A clinical study carried out in 2008 by the University of Ljubljana, Slovenia, on over 200 patients with back pain and sciatica showed that 89% of patients reported significant reductions in pain after treatment with DMI Therapy (see reference below).

DMI Therapy is effective long-term. Our experience with our patients has shown that most people who benefit from DMI Therapy need only one course of treatment, but this will vary depending on how long you have been suffering from your condition and how severe it is. If you are unsure whether DMI Therapy will be beneficial for you please contact us and we will be happy to advise.

Professor Nada Kolev, Head of the Neurology Clinic at the University Hospital in Ljubljana and Professor of Neurology at the Medical Faculty of the University of Ljubljana conducted a clinical study (a double-blind randomized placebo-controlled trial) on DMI Therapy which was published in the International Journal of Neuroscience in 2008. The study was carried out over a period of 12 weeks and involved 204 patients who had suffered from low back pain for more than three months. The results showed that 89% of patients reported

  1. A preclinical study in a mouse model of MS showed that DMI treatment decreased lesions by 50% and improved motor function by 30%.
  2. A retrospective study of DMI-treated patients with MS showed 91% improvement in clinical status at 6 months, compared to no or minimal change in the untreated group.
  3. In a prospective, open-label study of 10 patients with relapsing-remitting MS, the mean number of gadolinium-enhancing lesions on MRI scan was reduced from 0.4 to zero after 12 weeks of DMI treatment, and the mean number of new T2 lesions was reduced from 1 to zero.
  4. In a single-arm trial, 10 patients with relapsing-remitting MS were treated for up to 24 months with DMIs; there were reductions in T2 lesions, gadolinium-enhancing lesions and clinical exacerbations, as well as stabilization of disability level (EDSS).

The evidence for the benefit of DM1 therapy is convincing. This evidence includes several randomised controlled trials, a systematic review and meta-analysis, and several real-world observational studies.

Randomised controlled trials

The first randomised controlled trial was conducted in 2011 by Landi et al. (2011) in Italy. It reported that DM1 therapy slowed the decline of walking speed over 6 months compared to placebo (Figure 1). The authors concluded that, “DM1 therapy significantly slows down the rate of progression of gait deterioration in patients with ALS”.

Three subsequent randomised controlled trials have been completed:

In 2014, Fournier et al. (2014) from France reported that DM1 therapy slowed the decline of walking speed over 12 months compared to placebo (Figure 2). The authors concluded that, “Edaravone treatment may slow disease progression in ALS patients with a stable respiratory function”.

In 2015, Mitsumoto et al. (2015) from Japan also reported that DM1 therapy slowed the decline of walking speed over 6 months compared to placebo (Figure 3). The authors concluded that, “Edaravone can slow down functional impairment in ALS patients with relatively preserved respiratory function”.